Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym M (ALVR-105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
A study to evaluate ALVR105 (Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.
Primary: The primary objective is to compare the time to resolution of macroscopic hematuria in recipients of Viralym-M (also known as ALVR-105) to that in patients receiving placebo.
The key secondary objective is to compare the time to resolution of bladder pain as measured by Clinical Outcome Assessments (COAs) in recipients of Viralym-M to that in patients receiving placebo.
Other secondary objectives include comparisons of the following in recipients of Viralym-M and patients receiving placebo:
* To assess number of days in the hospital (for any reason including, but not limited to, HC) over the 24-week study period
* To assess the incidence and severity of acute GVHD and CRS over the 24-week study period
* To assess time to resolution of viremia for all target viruses over the 24-week study period (only for patients with detectable viremia at baseline)
* To assess average daily bladder pain (11-point numeric rating scale [NRS]) over the 6-week period from randomization
Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year prior to randomization.
Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3 consecutive laboratory values obtained on different days, and platelet count >10,000/mm³ at the time of randomization.
Diagnosed with HC based on the following criteria (all 3 criteria must be met):
Clinical signs and symptoms of cystitis, including dysuria, lower abdominal pain, and/or other bladder-associated pain or spasms.
Grade > 3 hematuria, defined as macroscopic hematuria with visible clots.
Viruria of >5 log10 copies/mL of at least 1 target virus (ie, BKV, JCV, AdV, CMV, EBV, and/or HHV-6).
At least 1 identified, suitably matched ALVR105 cell line for infusion is available
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub